FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/06/2024
Voltar para busca
Dado oficial do USPTO
AMPHIPROTECH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
06/06/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
30/11/2022
Data de registro
05/03/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/03/2024
Última transação
05/03/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
CN
Examinador
CLYBURN, DIONNE
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Shanghai Puyou Biomedical Co., Ltd.
Representantes
David M. Perry Blank Rome LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for human purposes, namely, pharmaceutical preparations for the treatment of cancer and antibiotics; Medicines for human purposes for the prevention and treatment of liver diseases; Medicines for human purposes for the prevention and treatment of respiratory system disorders; Medicines for human purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Medicines for human purposes for the prevention and treatment of gastro-intestinal diseases; Medicines for human purposes for the prevention and treatment of immune system related diseases and disorders; Medicines for human purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Chemical preparations for pharmaceutical purposes for the treatment of infectious diseases, blood disorders, immune system related diseases, tumours, thyroid disease, cardiovascular and cerebrovascular diseases, inflammation and cancer; Biological preparations for medical purposes for the treatment of cancer, insomnia and heart disease; Biological preparations for medical purposes for the prevention and treatment of liver diseases; Biological preparations for medical purposes for the prevention and treatment of respiratory system disorders; Biological preparations for medical purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Biological preparations for medical purposes for the prevention and treatment of gastro-intestinal diseases; Biological preparations for medical purposes for the prevention and treatment of immune system related diseases and disorders; Biological preparations for medical purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Drugs, namely, insulin for the treatment of diabetes for medical purposes; Pharmaceutical preparations, namely, analgesics, antibiotics and aspirin; Pharmaceutical preparations for the prevention and treatment of liver diseases; Pharmaceutical preparations for the prevention and treatment of respiratory system disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; Pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Medicines in form of tablet form for the treatment of cancer, insomnia and heart disease; Medicines in form of tablet form for the prevention and treatment of liver diseases; Medicines in form of tablet form for the prevention and treatment of respiratory system disorders; Medicines in form of tablet form for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Medicines in form of tablet form for the prevention and treatment of gastro-intestinal diseases; Medicines in form of tablet form for the prevention and treatment of immune system related diseases and disorders; Medicines in form of tablet form for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Biochemical medicines for the treatment of cancer, insomnia and heart disease; Biochemical medicines for the prevention and treatment of liver diseases; Biochemical medicines for the prevention and treatment of respiratory system disorders; Biochemical medicines for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Biochemical medicines for the prevention and treatment of gastro-intestinal diseases; Biochemical medicines for the prevention and treatment of immune system related diseases and disorders; Biochemical medicines for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Capsules for medicines for the treatment of cancer, insomnia and heart disease; Capsules for medicines for the prevention and treatment of liver diseases; Capsules for medicines for the prevention and treatment of respiratory system disorders; Capsules for medicines for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases, diabetes; Capsules for medicines for the prevention and treatment of gastro-intestinal diseases; Capsules for medicines for the prevention and treatment of immune system related diseases and disorders; Capsules for medicines for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Injectable medicinal solutions, namely, dermal fillers; Injectable medicinal solutions, namely, injectable contraceptives; Dietetic foods and beverages adapted for medical use; Dietetic preparations adapted for medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
05/03/2024
GPNX
NOTIFICATION PROCESSED BY IB
19/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/12/2023
PUBO
PUBLISHED FOR OPPOSITION
19/12/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/11/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/11/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/11/2023
RFNT
REFUSAL PROCESSED BY IB
17/10/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/09/2023
RFRR
REFUSAL PROCESSED BY MPU
28/09/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/09/2023
CNRT
NON-FINAL ACTION WRITTEN
15/09/2023
DOCK
ASSIGNED TO EXAMINER
09/09/2023
MAFR
APPLICATION FILING RECEIPT MAILED
24/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/01/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
19/01/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AMPHIPROTECH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.